Peptide Half-Life: What Sets It and How Analogs Extend It

Most native peptides disappear from circulation in minutes. Nearly every engineered analog in a research catalogue exists because someone set out to change that, and the modifications used are a small, recognisable set.

Why native peptides clear quickly

Three routes dominate. Exopeptidases trim residues from the termini; dipeptidyl peptidase-4 is the best-known example, cleaving after a proline or alanine at position 2. Endopeptidases cut internally at recognised motifs. And small peptides below roughly 5 kDa are cleared renally by glomerular filtration, which no amount of protease resistance prevents.

An analog that solves only one of these does not necessarily gain much exposure, which is why modifications are often combined.

The four strategies

Substitution at the cleavage site

Replacing the residue an enzyme recognises blocks that enzyme. The classic case is substituting the position-2 alanine in incretin peptides to resist DPP-4. Substituting a D-amino acid works more broadly, since proteases are stereospecific and generally cannot process D-residues.

Albumin binding

Attaching a group that binds serum albumin — a fatty-acid chain, or a reactive group that forms a covalent conjugate — makes the peptide travel with a protein that has a multi-day circulating half-life. This is the mechanism behind the DAC modification, covered in our note on CJC-1295 with and without DAC.

Cyclisation and backbone constraint

A cyclic backbone has no free termini for exopeptidases and is conformationally constrained, which can also improve receptor selectivity. The trade-off is synthetic complexity and additional analytical work, since cyclisation isomers can co-elute with the target.

Increasing effective size

Conjugation to a larger carrier raises the molecule above the renal filtration threshold. This is the least common approach in short research peptides because it changes the molecule substantially.

Reading half-life figures critically

A quoted half-life is species-specific and route-specific. A rodent figure does not transfer to another species, and an in vitro plasma stability half-life is not the same measurement as an in vivo circulating half-life. When two sources disagree, the usual explanation is that they measured different things. The medicinal chemistry literature on these strategies is indexed at PubMed.

Related: peptide nomenclature — analogs, fragments and salts.

ExoLabz supplies compounds for laboratory research use only. Nothing on this page is medical advice or a suggestion of human or veterinary use. Certificates of analysis are published on this site.